Search

Samuel A Acquah

Examiner (ID: 1213)

Most Active Art Unit
1711
Art Unit(s)
2899, 1207, 1711, 1503, 1774, 1754
Total Applications
2690
Issued Applications
2329
Pending Applications
91
Abandoned Applications
269

Applications

Application numberTitle of the applicationFiling DateStatus
Array ( [id] => 17334688 [patent_doc_number] => 20220001019 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-01-06 [patent_title] => RANDOM CONJUGATE MOLECULE AND METHODS OF MAKING AND USING THE SAME [patent_app_type] => utility [patent_app_number] => 16/839717 [patent_app_country] => US [patent_app_date] => 2020-04-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 27214 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 31 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16839717 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/839717
RANDOM CONJUGATE MOLECULE AND METHODS OF MAKING AND USING THE SAME Apr 2, 2020 Abandoned
Array ( [id] => 16691668 [patent_doc_number] => 20210074147 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-03-11 [patent_title] => PROLACTIN RECEPTOR BINDING PROTEINS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 16/828351 [patent_app_country] => US [patent_app_date] => 2020-03-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 69105 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -33 [patent_words_short_claim] => 32 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16828351 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/828351
PROLACTIN RECEPTOR BINDING PROTEINS AND USES THEREOF Mar 23, 2020 Abandoned
Array ( [id] => 16691668 [patent_doc_number] => 20210074147 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-03-11 [patent_title] => PROLACTIN RECEPTOR BINDING PROTEINS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 16/828351 [patent_app_country] => US [patent_app_date] => 2020-03-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 69105 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -33 [patent_words_short_claim] => 32 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16828351 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/828351
PROLACTIN RECEPTOR BINDING PROTEINS AND USES THEREOF Mar 23, 2020 Abandoned
Array ( [id] => 19505186 [patent_doc_number] => 12116598 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-10-15 [patent_title] => Thymic epithelial cells, exosomes derived therefrom, and methods of making and using same [patent_app_type] => utility [patent_app_number] => 16/823737 [patent_app_country] => US [patent_app_date] => 2020-03-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 15 [patent_no_of_words] => 8704 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 64 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16823737 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/823737
Thymic epithelial cells, exosomes derived therefrom, and methods of making and using same Mar 18, 2020 Issued
Array ( [id] => 16111663 [patent_doc_number] => 20200207854 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-07-02 [patent_title] => HUMANIZED AFFINITY MATURED ANTI-FcRn ANTIBODIES [patent_app_type] => utility [patent_app_number] => 16/800458 [patent_app_country] => US [patent_app_date] => 2020-02-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28464 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -6 [patent_words_short_claim] => 132 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16800458 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/800458
HUMANIZED AFFINITY MATURED ANTI-FcRn ANTIBODIES Feb 24, 2020 Abandoned
Array ( [id] => 16012839 [patent_doc_number] => 20200181262 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-06-11 [patent_title] => HUMANIZED AFFINITY MATURED ANTI-FcRn ANTIBODIES [patent_app_type] => utility [patent_app_number] => 16/800480 [patent_app_country] => US [patent_app_date] => 2020-02-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28460 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 151 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16800480 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/800480
HUMANIZED AFFINITY MATURED ANTI-FcRn ANTIBODIES Feb 24, 2020 Abandoned
Array ( [id] => 15931195 [patent_doc_number] => 20200157231 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-05-21 [patent_title] => DIAGNOSIS AND TREATMENT OF CANCER USING ANTI-LGR7 ANTIBODY [patent_app_type] => utility [patent_app_number] => 16/782728 [patent_app_country] => US [patent_app_date] => 2020-02-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24920 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16782728 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/782728
DIAGNOSIS AND TREATMENT OF CANCER USING ANTI-LGR7 ANTIBODY Feb 4, 2020 Abandoned
Array ( [id] => 19551096 [patent_doc_number] => 12134795 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-11-05 [patent_title] => Sensor for cyanuric acid detection [patent_app_type] => utility [patent_app_number] => 16/750465 [patent_app_country] => US [patent_app_date] => 2020-01-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 10 [patent_no_of_words] => 7241 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 126 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16750465 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/750465
Sensor for cyanuric acid detection Jan 22, 2020 Issued
Array ( [id] => 15866233 [patent_doc_number] => 20200140520 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-05-07 [patent_title] => IMMUNOSUPPRESSIVE TGF-B SIGNAL CONVERTER [patent_app_type] => utility [patent_app_number] => 16/743987 [patent_app_country] => US [patent_app_date] => 2020-01-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15914 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -2 [patent_words_short_claim] => 29 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16743987 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/743987
IMMUNOSUPPRESSIVE TGF-B SIGNAL CONVERTER Jan 14, 2020 Pending
Array ( [id] => 16420527 [patent_doc_number] => 20200345725 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-11-05 [patent_title] => Methods and Compositions for Treating Cancer [patent_app_type] => utility [patent_app_number] => 16/740187 [patent_app_country] => US [patent_app_date] => 2020-01-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 121097 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -67 [patent_words_short_claim] => 27 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16740187 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/740187
Methods and Compositions for Treating Cancer Jan 9, 2020 Abandoned
Array ( [id] => 19275489 [patent_doc_number] => 12025612 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-07-02 [patent_title] => Brown adipocyte progenitors in human skeletal muscle [patent_app_type] => utility [patent_app_number] => 16/713048 [patent_app_country] => US [patent_app_date] => 2019-12-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 16 [patent_no_of_words] => 10156 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 94 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16713048 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/713048
Brown adipocyte progenitors in human skeletal muscle Dec 12, 2019 Issued
Array ( [id] => 16837952 [patent_doc_number] => 20210145964 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-05-20 [patent_title] => STROMA-TARGETING TREATMENT FOR PATIENTS WITH ELEVATED ADAM12 LEVELS [patent_app_type] => utility [patent_app_number] => 16/685100 [patent_app_country] => US [patent_app_date] => 2019-11-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15399 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -23 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16685100 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/685100
STROMA-TARGETING TREATMENT FOR PATIENTS WITH ELEVATED ADAM12 LEVELS Nov 14, 2019 Pending
Array ( [id] => 16087059 [patent_doc_number] => 20200197516 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-06-25 [patent_title] => Antagonists of Products of the HS.459642 Unigene Cluster for the Inhibition of Proliferation, Development or Differentiation of Stem Cells Including Cancer Stem Cells [patent_app_type] => utility [patent_app_number] => 16/685279 [patent_app_country] => US [patent_app_date] => 2019-11-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11537 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16685279 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/685279
Antagonists of Products of the HS.459642 Unigene Cluster for the Inhibition of Proliferation, Development or Differentiation of Stem Cells Including Cancer Stem Cells Nov 14, 2019 Abandoned
Array ( [id] => 16091393 [patent_doc_number] => 20200199683 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-06-25 [patent_title] => METHODS FOR EVALUATING AND TREATING WALDENSTROM'S MACROGLOBULINEMIA [patent_app_type] => utility [patent_app_number] => 16/684193 [patent_app_country] => US [patent_app_date] => 2019-11-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19237 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16684193 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/684193
METHODS FOR EVALUATING AND TREATING WALDENSTROM'S MACROGLOBULINEMIA Nov 13, 2019 Abandoned
Array ( [id] => 15893501 [patent_doc_number] => 20200146269 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-05-14 [patent_title] => METHODS AND COMPOSITIONS FOR MODULATING INNATE LYMPHOID CELL PATHOGENIC EFFECTORS [patent_app_type] => utility [patent_app_number] => 16/681050 [patent_app_country] => US [patent_app_date] => 2019-11-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 51138 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16681050 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/681050
METHODS AND COMPOSITIONS FOR MODULATING INNATE LYMPHOID CELL PATHOGENIC EFFECTORS Nov 11, 2019 Pending
Array ( [id] => 17385923 [patent_doc_number] => 20220033775 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-02-03 [patent_title] => EXPANSION OF TILS UTILIZING AKT PATHWAYS INHIBITORS [patent_app_type] => utility [patent_app_number] => 17/290639 [patent_app_country] => US [patent_app_date] => 2019-11-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 146954 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -28 [patent_words_short_claim] => 81 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17290639 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/290639
EXPANSION OF TILS UTILIZING AKT PATHWAYS INHIBITORS Nov 3, 2019 Pending
Array ( [id] => 17334562 [patent_doc_number] => 20220000893 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-01-06 [patent_title] => METHOD FOR TREATING T-HELPER TYPE 2 MEDIATED DISEASE [patent_app_type] => utility [patent_app_number] => 17/289413 [patent_app_country] => US [patent_app_date] => 2019-10-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15184 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17289413 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/289413
METHOD FOR TREATING T-HELPER TYPE 2 MEDIATED DISEASE Oct 29, 2019 Pending
Array ( [id] => 15524819 [patent_doc_number] => 20200054715 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-02-20 [patent_title] => TREATMENT OF COLLAGEN DEFECTS USING PROTEIN SOLUTIONS [patent_app_type] => utility [patent_app_number] => 16/665975 [patent_app_country] => US [patent_app_date] => 2019-10-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18144 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16665975 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/665975
Treatment of collagen defects using protein solutions Oct 27, 2019 Issued
Array ( [id] => 16296349 [patent_doc_number] => 20200282072 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-09-10 [patent_title] => ANTI-EGFR ANTIBODY DRUG CONJUGATE FORMULATIONS [patent_app_type] => utility [patent_app_number] => 16/655716 [patent_app_country] => US [patent_app_date] => 2019-10-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 34205 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16655716 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/655716
ANTI-EGFR ANTIBODY DRUG CONJUGATE FORMULATIONS Oct 16, 2019 Abandoned
Array ( [id] => 15901177 [patent_doc_number] => 20200150107 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-05-14 [patent_title] => COMPOUNDS FOR TREATMENT OF DISEASES AND METHODS OF SCREENING THEREFOR [patent_app_type] => utility [patent_app_number] => 16/653874 [patent_app_country] => US [patent_app_date] => 2019-10-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 43758 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -24 [patent_words_short_claim] => 85 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16653874 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/653874
COMPOUNDS FOR TREATMENT OF DISEASES AND METHODS OF SCREENING THEREFOR Oct 14, 2019 Pending
Menu